Candibene

Quick links to important sections

Candibene

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Candibene

Quick Facts

Property Description
Active ingredient Clotrimazol
Form Cream, solution, vaginal tablet, lozenge
Pharmacological class Azole antifungal (Imidazole derivative)
Common use Treatment of infections caused by fungi and yeasts
Origin Synthetic

The Definitive Classification of Candibene

Candibene is a pharmaceutical drug defined by its active ingredient, Clotrimazol, which is classified as a synthetic azole antifungal agent and a broad-spectrum antimycotic. Clotrimazol belongs to the chemical group of imidazole derivatives, confirming its primary purpose is the targeted intervention against fungi and yeasts. Pharmacological studies have established Clotrimazol as a clinically recognized standard for addressing superficial fungal infections, a standing that supports its wide availability and use. This monopreparation relies exclusively on the effect of Clotrimazol, distinguishing it as a dedicated medication engineered solely for mycotic organisms.

Composition, Forms, and Non-Systemic Use

Clotrimazol is a synthetic compound that is formulated for localized application, ensuring its action is non-systemic and concentrated at the affected site. The drug is available in multiple dosage forms, including a cream and a solution for skin application, as well as specialized preparations such as vaginal tablets and oral lozenges. This variety in preparation is a key differentiator, allowing for the most appropriate delivery method for the infection's location, such as using the cream for common conditions like athlete's foot. These forms enable targeted delivery through topical, intravaginal, or transmucosal routes of administration, which is critical for maximizing the active ingredient's concentration directly on the affected membrane.

General Therapeutic Purpose and Action Type

The primary therapeutic purpose of Candibene is the control and resolution of superficial infections caused by specific fungi and yeasts susceptible to Clotrimazol. The function is rooted in its ability to inhibit the synthesis of ergosterol, a critical structural component of the fungal cell membrane, leading to structural and functional impairment. This mechanism results in a powerful dual action: it is both fungistatic—meaning it stops the fungal cells from growing and spreading—and fungicidal, actively eliminating the existing fungal population to resolve the infection.

What side effects are possible with Candibene?

Possible side effects and safety information

The safety profile of Candibene (Clotrimazol) is predominantly defined by localized application site reactions, reflecting its non-systemic use in most topical and vaginal forms. These reactions, which are recognized in regulatory documents as the most frequently reported adverse effects, typically occur where the medication is applied and may diminish with continued treatment.


Adverse Reactions and Regulatory Classification

Adverse reactions are classified by frequency and System-Organ Class (SOC) according to regulatory standards.

Commonly Documented Local Reactions

Side effects that are commonly observed in clinical data include a burning sensation, pruritus (itching), and irritation at the application site or vulvovaginal area. These local effects are generally confined to the skin or mucosa.

Reactions with Frequency Not Known

Based on post-marketing spontaneous reports, a range of reactions are documented with a frequency classified as not known. These include oedema (swelling), exfoliation (peeling), and blistering of the skin, as well as nausea or abdominal pain (particularly relevant for the oral lozenge form).

Serious Adverse Reactions

The regulatory documentation for Clotrimazol explicitly lists anaphylactic reaction and angioedema under the Immune System Disorders category. These are rare, severe systemic allergic responses that underscore the potential, though minimal, for generalized reactions.


Safety Considerations and Constraints

Regulatory safety statements include important constraints for specific formulations and populations:

  • Contraceptive Restriction: The vaginal formulations may cause damage to latex products, such as condoms and diaphragms, which can lead to reduced effectiveness. Alternative protective measures are advised during treatment and for a period afterward.
  • Hepatic Monitoring: For the oral lozenge, periodic monitoring of liver function tests is recommended for individuals with pre-existing hepatic impairment.
  • Pediatric and Pregnancy Use: Safety of the oral lozenge is not established for children below three years. Topical and vaginal use during pregnancy is typically advised under medical supervision.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Candibene addresses potential overdose scenarios based on the drug's different formulations and limited systemic absorption.

Feature Official Regulatory Statement
Severity classification Acute overdosage from topical or vaginal application is officially classified as unlikely to lead to a life-threatening situation due to negligible systemic exposure.
Accidental Ingestion Signs Accidental oral ingestion of topical formulations may result in documented clinical manifestations, including dizziness, nausea, and vomiting.
Emergency-response Seek immediate medical attention for any suspected overdose. Contact with a Poison Control Center is required immediately.
Urgent Help Required Regulatory guidance mandates contacting emergency services if severe, acute systemic events occur, such as collapse, seizure, trouble breathing, or inability to be awakened.

Resulting Overdose Structure

Official statements confirm that the risk from dermal or vaginal overdosage is low, defining it as unlikely to cause a severe outcome. The need for urgent medical help is primarily linked to the appearance of severe, life-threatening clinical signs, which may be associated with the oral lozenge form. In cases of accidental oral ingestion of a non-oral formulation, supportive management is required. Regulatory documentation indicates that a procedure like gastric lavage should be considered only if the patient exhibits documented manifestations such as dizziness, nausea, or vomiting. No specific antidote for Clotrimazol overdose is documented in the official prescribing information, and the management focus remains on treating symptoms and providing supportive care.

Therapeutic Uses of Candibene

What Candibene Treats: Main Uses and Benefits

Candibene is used in situations involving certain distressing symptoms caused by susceptible fungi and yeasts. This medication is commonly used across therapeutic areas where symptomatic management is appropriate.


Targeting Superficial Fungal Skin Conditions

Candibene is commonly used to help with symptoms that create noticeable physiological strain caused by fungal infections known as dermatomycoses. This is considered relevant for conditions such as Tinea Pedis, Tinea Cruris, and Tinea Corporis. It is commonly used to help with symptoms related to inflammatory or irritative states, which may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Alleviating Pruritus, Burning, and Irritation

The medication is relevant in clinical settings marked by increased discomfort or tension, particularly when symptom clusters, such as intense itching (pruritus), a pronounced burning sensation, and skin irritation, become more noticeable. It is applied in scenarios where additional management of discomfort is required, which may assist patients in coping more steadily with symptoms that interfere with daily functioning and contributes to improved day-to-day comfort during periods of heightened symptoms.


Quick Fact: Therapeutic Use

The medication is commonly used for conditions involving recurrent or episodic manifestations of mycotic origin, and may offer supportive relief for symptoms such as intense itching, redness, and the burning sensation associated with localized discomfort.

Regulatory References

  1. NIH MedlinePlus overview of Clotrimazole Topical

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Candibene

Populations for whom use is contraindicated:

  • Patients with known hypersensitivity to clotrimazole or any ingredient in the specific formulation.
  • Individuals with a known allergy to imidazole antifungals are generally prohibited from use.

Age-Related Eligibility Rules

  • Topical preparations are generally established for use in adults and children.
  • Vaginal formulations are typically not recommended for self-use in girls under 12 years of age or women over 60 years, who should seek medical advice prior to use.

Condition-Specific Eligibility Rules

  • Self-treatment is prohibited if the patient presents with severe symptoms such as fever, lower abdominal pain, abnormal/blood-stained discharge, or vulval sores, as these signs require immediate medical consultation.
  • The use of this product may cause damage to latex contraceptives (condoms, diaphragms), and alternative barrier precautions are required during treatment.

Pregnancy and Lactation Eligibility Status

  • Use during the first trimester of pregnancy is not recommended. Use in the second and third trimesters is permitted, but only under medical supervision.
  • Use may be permitted during lactation, though some regulators advise caution due to a lack of human data on excretion into breast milk.

What should I know about interactions with other medicines?

Candibene, which contains clotrimazole, is primarily a topical or local antifungal agent, meaning systemic drug absorption is generally minimal. However, interactions are documented, particularly with the oral lozenge form and with intravaginal use.

Documented Pharmacokinetic Interactions

Clotrimazole, when absorbed systemically (chiefly from the oral lozenge), can affect the metabolism of other drugs. It may increase the serum concentration of certain immunosuppressants, such as tacrolimus and sirolimus. For this reason, patients taking such medicines should be closely monitored by a healthcare professional.

Additionally, clotrimazole may increase the therapeutic efficacy of oral anticoagulants, like warfarin. Patients on these blood thinners may require careful monitoring of their clotting profile (INR) and potential dose adjustments.

Interactions with Other Products

Intravaginal preparations of clotrimazole are known to damage latex contraceptive devices, including condoms, diaphragms, and cervical caps. This damage can lead to a failure of the device, rendering it ineffective for contraception or protection against sexually transmitted diseases. Patients should avoid using these latex devices during treatment with intravaginal clotrimazole.

Topical or lozenge clotrimazole may also exhibit antagonistic or synergistic effects with other antifungal agents, such as amphotericin or nystatin, although the clinical significance of these effects can vary.

Mechanism of Action

Targeted Inhibition of Fungal Sterol Synthesis

The drug's primary action is executed through the mechanism of enzyme inhibition. Clotrimazol acts as a specific inhibitor against lanosterol 14-alpha demethylase (CYP51), a cytochrome P450 enzyme essential for the fungal cell. By binding to the CYP51 enzyme, the drug blocks the critical demethylation step, immediately shutting down the biosynthesis of ergosterol, which is vital for fungal cell membrane structure.


Cascade of Membrane Damage and Cell Lysis

The resultant lack of ergosterol causes toxic precursor molecules to accumulate within the fungal cytoplasmic membrane, leading to its functional destabilization and compromised integrity. This functional breakdown of the cell barrier results in the rapid, uncontrolled leakage of essential intracellular contents, such as potassium ions and phosphorus compounds. This loss of cellular homeostasis ultimately causes the elimination of the mycotic organism through metabolic collapse.


Mechanistic Constraints

While the mechanism is highly selective toward fungal metabolic processes, its action is constrained by resistance mechanisms. Fungal strains can develop efflux pumps that actively expel the drug, limiting its concentration at the CYP51 target. Furthermore, the fungicidal action is most effective against actively proliferating cells, demonstrating limited activity against quiescent fungal spores.

Dosage and Administration Information

Official Administration Routes and Regimens

Candibene (Clotrimazol) is administered via localized, non-systemic routes: Topical (Dermal), Intravaginal, and Transmucosal (Oral). The official dosing schedule is determined by the specific form and application site. Topical preparations, such as the 1% cream or solution, are generally applied as a thin layer to the affected area two to three times per day. The total duration of use for skin infections is typically fixed, ranging from two to eight weeks depending on the specific diagnosis.

Intravaginal regimens utilize specialized forms, including 100 mg, 200 mg, or a single 500 mg vaginal tablet. These courses are commonly structured for one, three, or seven consecutive days, and the application is typically scheduled once daily at bedtime to aid retention. Dosing for topical applications generally follows the adult regimen for pediatric patients over 3 years of age, while vaginal preparations are intended for those over 12 years of age.

Administration Specifics and Timing

Contextual instructions for proper use are critical for efficacy. The 10 mg oral lozenge regimen requires administration five times per day for treatment, with doses spaced approximately 3 to 4 hours apart. The lozenge must be allowed to dissolve slowly in the mouth over 30 minutes and must not be chewed or swallowed whole to ensure localized delivery to the oral cavity. For topical use, the preparation must be gently rubbed into the skin. If any dose is missed, it should be applied as soon as remembered, unless it is nearly time for the next scheduled dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Candibene

Evidence for Use in Fungal Skin Infections (Dermatomycoses)

Research exploring the use of Candibene for fungal skin conditions, such as athlete's foot and ringworm, primarily consists of Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies examine how symptoms change over defined time intervals and measure outcomes related to physical discomfort. Research focuses on two main areas: mycological cure (clearance of the fungus confirmed in laboratory settings) and clinical cure (patient-reported outcomes describing perceived discomfort and resolution of visible signs).

Studies monitored changes in both fungal presence and patient symptoms over defined intervals, and findings describe patterns observed in the studied cohorts. The evidence so far suggests that the studies contribute to the broader evidence landscape related to these conditions, but long-term patient outcomes regarding infection recurrence are not consistently documented across all available research.

Evidence for Use in Vaginal and Oral Yeast Infections

For Vulvovaginal Candidiasis, the evidence landscape is shaped by numerous RCTs exploring different multi-day regimens of the vaginal tablets. These studies monitored patterns related to mycological endpoints and measurements of symptom score changes within the defined follow-up periods. For Oropharyngeal Candidiasis (oral thrush), studies primarily utilize the lozenge formulation, often conducted among special populations, including those who are immunocompromised. Research describes patterns related to fungal clearance and lesion resolution, although reports also described the challenges associated with patient adherence to the required multi-dosing schedule.

Data for certain groups remain insufficient, particularly regarding the structure of evidence for recurrent or complicated cases of candidiasis. Comparative evidence against newer agents is often lacking or mixed across various meta-analyses.

Research Gaps and Areas of Uncertainty

Systematic reviews of the research landscape indicate that comparative evidence against the newest antifungal agents is often lacking across all indications, and older trials sometimes carry limitations in reporting quality. Follow-up durations were limited across the majority of studies, meaning there is limited information for long-term outcomes regarding the recurrence of infection. Research provides context but not individual predictions, and the available evidence contributes primarily to understanding short-term symptom patterns under the specific conditions studied.

Key Studies & References

  1. NIH Bookshelf: Vulvovaginal Candidiasis Treatment Regimens and Evidence
  2. NIH Bookshelf: Vaginal Candidiasis in Pregnancy and Special Populations

Frequently Asked Questions (FAQ)

Common questions about Candibene (FAQ)


Q: Is Candibene a cream or a tablet?

According to the official product information, Candibene is available in multiple forms, including a cream and solution for skin application, as well as specialized vaginal tablets and oral lozenges. This variety ensures the appropriate formulation can be used to deliver the active ingredient directly to the site of the infection.


Q: What is the difference between Candibene cream and the solution?

Official instructions describe the solution form as being typically used for applying the drug to larger areas of skin or on areas covered by hair. The cream formulation is generally applied as a thin layer to specific affected skin areas.


Q: Why is Candibene available over-the-counter in some places but not others?

The classification of any medication, determining if it is available over-the-counter (OTC) or requires a prescription, is managed by regulatory bodies within each country or region. Therefore, the availability of Candibene and its different strengths can vary globally depending on local regulatory decisions.


Q: Does Candibene help with general skin irritation?

The drug is officially classified as an antifungal agent intended for treating infections caused specifically by fungi and yeasts. Its primary therapeutic purpose is not described as including the treatment of general skin irritation that is not linked to a fungal infection.


Q: What should I expect in the first few days of using Candibene?

Official patient information suggests that symptom improvement may begin within the first few days or the first week of using the product. If symptoms worsen or if no improvement is seen after a certain period, regulatory guidance describes conditions that warrant professional input.


Q: If I miss a time to use it, what am I supposed to do?

Regulatory dosing guidance states that if a dose is missed, it should generally be applied or taken as soon as it is remembered. However, if it is almost time for the next scheduled application, regulatory guidance indicates the missed dose is typically skipped.


Q: What happens if I stop using Candibene too early?

Regulatory guidance suggests that not completing the full recommended treatment duration may reduce the intended therapeutic effect. Therefore, patients are advised in the product information to complete the full course even if symptoms have resolved.


Q: What are some less common side effects reported by users?

Beyond the most common local reactions, less common reactions documented in post-marketing reports include swelling (oedema), peeling (exfoliation), and blistering of the skin at the application site. For the oral lozenge form, reports have included nausea or abdominal pain.


Q: Is a slight redness normal while using Candibene?

Redness is described in official documents as a possible local reaction or a sign of irritation at the application site, alongside sensations like burning or itching. If the redness is severe or appears to worsen, regulatory documents describe conditions that warrant input from a healthcare provider.


Q: Are there specific warnings about Candibene and sun exposure?

Official drug labels, which detail all known risks and precautions, do not typically list specific warnings or precautions regarding sun exposure or photosensitivity for the use of clotrimazole.


Q: Can Candibene affect birth control pills?

The drug is known to damage latex contraceptive devices, such as condoms and diaphragms, rendering them ineffective. However, official drug interaction documentation does not typically include warnings for oral contraceptive pills when using the topical or vaginal forms of the medication.


Q: Are there any known issues with using Candibene while drinking coffee?

Official drug interaction sections are focused on medicinal products and do not typically list specific interactions with common beverages like coffee or caffeine when using the topical, vaginal, or oral lozenge formulations.


Q: Does Candibene interact with common pain relievers like ibuprofen?

Official drug interaction documentation for the localized formulations of the drug does not typically list common pain relievers like ibuprofen as being known to interact with the medication.


Q: Are there special considerations for older adults using Candibene?

Regulatory documents state that vaginal formulations are generally not recommended for self-use in women over 60 years of age, who are noted in official documents as populations that should seek medical input prior to use.


Q: Does having a known allergy to other azole antifungals mean I can't use Candibene?

The active ingredient in Candibene is an imidazole antifungal, which is a chemical subclass of azoles. Official documentation contraindicates use in patients with a known hypersensitivity or allergy to imidazole antifungals.


Q: Is there evidence that Candibene works for nail issues?

Official patient counseling information for the topical formulation states that it is generally not effective for the treatment of nail infections.


Q: Why are there different strengths of Candibene available?

Different strengths and formulations are produced to match the specific route of administration—such as skin, vaginal, or oral application—and the type of fungal infection being treated. This ensures the appropriate concentration of the active ingredient is delivered to the affected area.


Q: Does Candibene have any effect on bacterial infections?

The drug is officially classified as a broad-spectrum antimycotic agent whose function is targeted against fungi and yeasts. It is not officially indicated for the treatment of bacterial infections.


Q: What is the purpose of the inactive ingredients in Candibene cream?

Inactive ingredients are components of the formulation, such as certain alcohols or stabilizers, that are included to ensure the product has the proper texture and stability. They also help the active ingredient to be applied and absorbed into the skin effectively.


Q: Are there different brand names that contain the same active ingredient as Candibene?

The active ingredient in Candibene is clotrimazole. Official sources confirm that clotrimazole is available under numerous other brand names and generic labels in different regions worldwide.


Q: Can Candibene expire?

Like all medicinal products, Candibene has a specified shelf life and must be stored and used according to the guidelines provided on the packaging. To ensure the maintenance of quality and efficacy, the product must be discarded after the expiration date printed on the package.


Q: If I see no change after a week, what does official information suggest?

Official self-medication guidance identifies conditions, such as lack of symptom improvement within a certain timeframe, that warrant input from a healthcare provider. The required timeframe before seeking input varies based on the condition being treated.


Q: Are there any food items that interact with Candibene?

When using the topical or vaginal formulations of the medication, official documentation does not typically list specific interactions with common food items.


Q: Does Candibene cause skin discoloration?

Skin discoloration is not typically listed as one of the commonly or less commonly documented adverse reactions in the regulatory documentation for the drug.


Q: Is Candibene commonly prescribed by general practitioners?

Based on available drug usage statistics from official sources, the active ingredient clotrimazole is frequently dispensed, indicating its common use in general clinical practice.


Q: Does Candibene come in a powder form?

The official product forms available include cream, solution, vaginal tablets, and oral lozenges. A dedicated powder formulation is not typically listed among the available final dosage forms for this product.


Q: Can using too much Candibene cause problems?

Accidental overuse of the topical formulation is generally not expected to cause a systemic reaction, as absorption into the bloodstream is minimal. However, excessive use may lead to increased local irritation or redness at the application site.


Q: Is it okay if I accidentally get a small amount of Candibene in my mouth?

If the topical or vaginal formulation is accidentally swallowed, official documentation recommends contacting a Poison Help line or seeking medical input for accidental ingestion.


Q: Does the evidence for Candibene cover all types of fungal infections?

Research evidence primarily covers the treatment of common superficial infections, such as those affecting the skin, vagina, and mouth. Systematic reviews note that data is limited regarding the treatment of recurrent or complicated cases of candidiasis.

How should Candibene be stored and disposed of?

How to Store and Dispose of Candibene?

Candibene must be stored according to regulatory guidelines to maintain its quality and efficacy. The product must be kept out of the sight and reach of children.

Storage Requirements

Requirement Official Instruction
Temperature Do not store above 25°C.
Packaging Store in the original package.
Protection Keep out of the sight and reach of children.

Disposal Instructions

Regulatory documents state that medicines should not be disposed of via household waste or wastewater, as these measures help to protect the environment. Any unused medicinal product or waste material must be disposed of in accordance with local requirements. Patients are typically advised to consult their pharmacist for guidance on how to properly dispose of medicines that are no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Candibene found in:

A-Z Index: